Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences (DE:IL3)
:IL3
Total Valuation
Integra Lifesciences has a market cap or net worth of €1.15B. The enterprise value is €3.46B.
Market Cap€1.15B
Enterprise Value€3.46B
Share Statistics
Integra Lifesciences has 77,204,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,204,640
Owned by Insiders3.28%
Owned by Institutions20.09%
Financial Efficiency
Integra Lifesciences’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 0.34%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)0.34%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee366.36K
Profits Per Employee-1.58K
Employee Count4,396
Asset Turnover0.40
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Integra Lifesciences is -251.52. Integra Lifesciences’s PEG ratio is 2.28.
PE Ratio-251.52
PS Ratio0.00
PB Ratio1.13
Price to Fair Value1.13
Price to FCF69.96
Price to Operating Cash Flow13.50
PEG Ratio2.28
Income Statement
In the last 12 months, Integra Lifesciences had revenue of 1.61B and earned -6.94M in profits. Earnings per share was -0.09.
Revenue1.61B
Gross Profit882.06M
Operating Income28.41M
Pretax Income-18.24M
Net Income-6.94M
EBITDA193.29M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was 129.38M and capital expenditures -114.37M, giving a free cash flow of 15.01M billion.
Operating Cash Flow129.38M
Free Cash Flow15.01M
Free Cash Flow per Share0.19
Dividends & Yields
Integra Lifesciences pays an annual dividend of €2.798, resulting in a dividend yield of ―
Dividend Per Share€2.798
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.77
52-Week Price Change-46.27%
50-Day Moving Average19.00
200-Day Moving Average20.37
Relative Strength Index (RSI)39.92
Average Volume (3m)8.00
Important Dates
Integra Lifesciences upcoming earnings date is May 5, 2025, TBA Not Confirmed.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 5, 2025
Ex-Dividend DateJul 02, 2015
Financial Position
Integra Lifesciences as a current ratio of 1.17, with Debt / Equity ratio of 128.43%
Current Ratio1.17
Quick Ratio0.71
Debt to Market Cap0.12
Net Debt to EBITDA-0.16
Interest Coverage Ratio0.40
Taxes
In the past 12 months, Integra Lifesciences has paid -11.29M in taxes.
Income Tax-11.29M
Effective Tax Rate0.62
Enterprise Valuation
Integra Lifesciences EV to EBITDA ratio is 8.88, with an EV/FCF ratio of 68.72.
EV to Sales1.07
EV to EBITDA8.88
EV to Free Cash Flow68.72
EV to Operating Cash Flow13.26
Balance Sheet
Integra Lifesciences has €273.57M in cash and marketable securities with $372.78M in debt, giving a net cash position of €1.71B billion.
Cash & Marketable Securities€273.57M
Total Debt$372.78M
Net Cash€1.71B
Net Cash Per Share€22.16
Tangible Book Value Per Share-€9.86
Margins
Gross margin is 55.18%, with operating margin of 1.76%, and net profit margin of -0.43%.
Gross Margin55.18%
Operating Margin1.76%
Pretax Margin-1.13%
Net Profit Margin-0.43%
EBITDA Margin12.00%
EBIT Margin3.25%
Analyst Forecast
The average price target for Integra Lifesciences is €21.77, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€21.77
Price Target Upside44.15% Upside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―